What drove the increase in Portfolio Receipts this quarter?

Portfolio Receipts rose 20% to $727 million, primarily driven by Royalty Receipts increases from Voranigo, Trelegy, Evrysdi, and Tremfya, as well as a one-time payment included in Milestones and other contractual receipts. Milestones and other contractual receipts were $56 million, compared with $3 million a year earlier.

How did full-year 2025 guidance change?

Portfolio Receipts guidance was raised to $3,050 million to $3,150 million, representing expected growth of 9% to 12%, from the prior range of $2,975 million to $3,125 million (growth of 6% to 12%). Guidance for payments for operating and professional costs was lowered to approximately 9% to 9.5% of Portfolio Receipts from approximately 10%, and interest paid guidance was raised to $275 million from $260 million.

Why did operating cash flow decline despite higher receipts?

Net cash provided by operating activities was $364 million versus $658 million a year earlier. The filing shows development-stage funding payments of $301 million in the quarter compared with $1 million in the prior-year quarter, and payments for operating and professional costs of $94 million compared with $48 million.

What is the status of the Vertex dispute?

In the second quarter of 2025, Royalty Pharma did not receive from Vertex the full amount of Royalty Receipts on Alyftrek net sales to which it is contractually entitled. The company has commenced the dispute resolution procedures contemplated by the agreements relating to its royalties on Vertex's cystic fibrosis products.

What is the company's capital return and balance sheet position?

The company repurchased approximately eight million Class A ordinary shares for $277 million in Q2 2025 and approximately 31 million shares for $1 billion in the first half of 2025, under a program authorizing up to $3.0 billion. As of June 30, 2025, cash and cash equivalents were $632 million and total debt principal was $8.2 billion.

RPRX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) reported second quarter 2025 results on August 6, 2025, as furnished in Exhibit 99.1 to this Form 8-K.

Portfolio Receipts rose 20% to $727 million^a, Royalty Receipts grew 11% to $672 million, and net cash provided by operating activities was $364 million, down from $658 million a year earlier. The company raised its full-year 2025 Portfolio Receipts guidance to $3,050 million to $3,150 million from $2,975 million to $3,125 million, and now expects growth of 9% to 12%. Management highlighted the closing in May 2025 of the internalization of its external manager, RP Management, LLC, which made the company an integrated public company.

Capital Deployment was $595 million^b in the quarter, including funding for daraxonrasib under a Revolution Medicines arrangement of up to $2 billion, and the company repurchased $1 billion of Class A ordinary shares in the first half of 2025. Cash and cash equivalents were $632 million and total debt principal was $8.2 billion as of June 30, 2025.

The filing also discloses that Royalty Pharma commenced dispute resolution procedures with Vertex because it did not receive the full amount of Royalty Receipts on Alyftrek net sales to which it is contractually entitled. Management noted that an Investor Day is scheduled for September 11th.

02—Key points

Key Highlights

Portfolio Receipts increased 20% to $727 million in Q2 2025, versus $608 million in Q2 2024, aided by a one-time payment within milestones and other contractual receipts.
Royalty Receipts grew 11% to $672 million, primarily driven by Voranigo, Trelegy, Evrysdi, and Tremfya.
Net cash provided by operating activities was $364 million, compared with $658 million in the prior-year quarter, and Adjusted EBITDA (non-GAAP) was $633 million.
Full-year 2025 Portfolio Receipts guidance was raised to $3,050 million to $3,150 million from $2,975 million to $3,125 million.
Capital Deployment was $595 million in Q2 2025, including a $200 million Adstiladrin milestone payment and funding for daraxonrasib under a Revolution Medicines arrangement of up to $2 billion.
Class A ordinary share repurchases totaled $1 billion in the first half of 2025, including $277 million in Q2 2025, and diluted weighted-average shares fell to 562 million from 597 million.
The internalization of external manager RP Management, LLC closed in May 2025 with 99.9% of votes cast in favor, and the company disclosed a dispute with Vertex over Alyftrek royalty receipts.

03—Questions

Frequently Asked Questions

What drove the increase in Portfolio Receipts this quarter?
Portfolio Receipts rose 20% to $727 million, primarily driven by Royalty Receipts increases from Voranigo, Trelegy, Evrysdi, and Tremfya, as well as a one-time payment included in Milestones and other contractual receipts. Milestones and other contractual receipts were $56 million, compared with $3 million a year earlier.
How did full-year 2025 guidance change?
Portfolio Receipts guidance was raised to $3,050 million to $3,150 million, representing expected growth of 9% to 12%, from the prior range of $2,975 million to $3,125 million (growth of 6% to 12%). Guidance for payments for operating and professional costs was lowered to approximately 9% to 9.5% of Portfolio Receipts from approximately 10%, and interest paid guidance was raised to $275 million from $260 million.
Why did operating cash flow decline despite higher receipts?
Net cash provided by operating activities was $364 million versus $658 million a year earlier. The filing shows development-stage funding payments of $301 million in the quarter compared with $1 million in the prior-year quarter, and payments for operating and professional costs of $94 million compared with $48 million.
What is the status of the Vertex dispute?
In the second quarter of 2025, Royalty Pharma did not receive from Vertex the full amount of Royalty Receipts on Alyftrek net sales to which it is contractually entitled. The company has commenced the dispute resolution procedures contemplated by the agreements relating to its royalties on Vertex's cystic fibrosis products.
What is the company's capital return and balance sheet position?
The company repurchased approximately eight million Class A ordinary shares for $277 million in Q2 2025 and approximately 31 million shares for $1 billion in the first half of 2025, under a program authorizing up to $3.0 billion. As of June 30, 2025, cash and cash equivalents were $632 million and total debt principal was $8.2 billion.

04—Continue

← View all 8-K filings